RxTrace to Sponsor the UDI Conference – May 26-28 – Baltimore, MD

Calling all medical device manufacturers, distributors, GPO’s, Providers, and healthcare industry stakeholders to make plans now to be in Baltimore in May! The 12th annual UDI Conference continues to be the platform for you to stay informed about the latest developments in UDI implementation, enabling technology, regulatory updates, Provider momentum, and Global expansion.

There is so much activity happening around UDI! The UDI Conference provides a knowledge sharing environment to explore and discuss the evolution of UDI. Collective problem solving is shared during the interactive sessions where the challenges, issues, progress & resources for ongoing UDI implementation, both within the US and internationally, will take place.

Attend to:

  • Take advantage of the UDI Boot Camp delivered by the FDA UDI Team.
  • Delve into the EU MDR & IVDR requirements in the 1/2 day Workshop.
  • Receive the latest regulatory instructions for Class I medical device manufacturers facing compliance in September 2020.
  • Break through the CHAOS of the expanding Global UDI-related initiatives.
  • Understand the influence of UDI across the healthcare eco-system.
  • Investigate technology solutions in the exhibit hall.

Subject matter experts and solution providers are available, both formally and informally, during the event to provide targeted guidance, recommendations and resources.

RxTrace Subscribers Receive $100 Savings:
Simply enter “RX” in the discount code field during registration to instantly save $100! Team registrations are always encouraged. If 2 or more from the same company are planning to attend, contact nicole@clariongroupinc.com to get a discount code. (Please note: only one discount code may be applied per registrant.)

Scholarships Offered:

As a way to provide an opportunity for all interested in UDI to participate in the annual event and join the dialogue, we have a number of Scholarships available for those who have a limited budget for conference registration. Contact nicole@clariongroupinc.com to discuss your needs.

Register today at http://www.udiconference.com/UDI_Conference/registration/
For additional conference details and the most up-to-date information, please visit http://www.udiconference.com/UDI_Conference/
For information on the FDA UDI Regulation & GUDID Guidance, visit www.FDA.gov/UDI.

The great thing about this conference is that it is co-sponsored by the FDA, so there will be lots of people from the FDA speaking and attending.  It’s so easy to get all your questions answered in one place at one time.  Don’t miss this opportunity!

See you all there!


ACTION REQUIRED: RxTrace Subscriber Update

To tell which type of notification email you are receiving, check the bottom line for the text “Email subscriptions powered by FeedBlitz. If you don’t see it, you are probably receiving the new WordPress notification emails. If you are confused, contact me.

Changes are coming to the way you connect with RxTrace.  Next month RxTrace will return to being free to everyone and open to all.  For the last year, all paid subscriptions have been pro-rated to end in March 2020.  As part of that approaching transition I will switch back to an email notification system that I used between 2010 and 2012.  It’s less configurable and less controllable…but it’s a free service!  What that means is, if you are currently receiving “Feedblitz” email notifications whenever new RxTrace essays are posted—whether on a paid or FREE subscriptionyou will need to “re-subscribe” to the “Wordpress” email notifications to continue receiving notices. Here’s how.

Continue reading ACTION REQUIRED: RxTrace Subscriber Update

WHO Publishes Draft Policy Brief for Medicines Traceability Regulations

Late last month the World Health Organization (WHO) published a draft “policy brief” for comments by February 28, 2020.  The draft is aimed at regulators of medicines around the world who might be considering the development of new medicines traceability mandates.  That pool of countries shrinks each year as more and more new mandates are announced, but considering the wide variations in the quality of the existing regulations, guidance aimed at those who would create new mandates is welcome.  Let’s take a look at the draft.

Continue reading WHO Publishes Draft Policy Brief for Medicines Traceability Regulations

What Happens To The FMD In the UK After Brexit Day? Seriously, Does Anyone Know?

Friday was “Brexit Day” in the United Kingdom—the last day the UK was a full member of the European Union.  At 11pm London time, the UK entered an 11 month “transition period” that will lead to the full exit on December 31, 2020.  On Wednesday the European Parliament voted overwhelmingly to accept the UK withdrawal agreement, but a lot more negotiations are necessary before a true “deal” is made.

Continue reading What Happens To The FMD In the UK After Brexit Day? Seriously, Does Anyone Know?

How The DSCSA Is Designed To Work

There are quite a few people people in the industry who misunderstand how the Drug Supply Chain Security Act (DSCSA) was designed to protect the supply chain. The most common misunderstanding is that it is a full “track and trace” system where drugs are verified at each step. In fact, the DSCSA is mainly just a breadcrumb system that forces companies in the supply chain to retain standardized documentation of supply chain events, “just in case”. Very few drug packages will ever get “verified” at any point in their existence in the supply chain. And that’s by design.

Continue reading How The DSCSA Is Designed To Work

The HHS Importation Proposed Rule

Last month the US Department of Health and Human Services (HHS) published a new notice of proposed rulemaking (NPRM) related to the importation of finished drugs from foreign supply chains–initially, only Canada but expandable in the future to other countries. The proposal is the result of President Trump’s initiative to lower the price of some medicines and it would invoke Section 804 of the Food, Drug and Cosmetics Act (FD&C)–inserted in the early 2000s–that envisions importation programs, under certain strict conditions. Programs under Section 804 can only be implemented if the Secretary of HHS certifies that the they will pose no additional risk to the public’s health and safety, and will result in a significant reduction in the cost of covered products to the American consumer (see “Can Trump/Azar/Sharpless Eliminate Parts of the DSCSA to Enable Importation?” and “Here We Go Again. Florida Flirts With Opening Door To Counterfeits“). Those are high bars. So high, that no Secretary of HHS has been willing to pursue Section 804 Importation Programs (SIPs) until the current one. Will the HHS proposed rule result in programs that pose no increased risk to American consumers? Let’s take a look and see if we can find the answer.

Continue reading The HHS Importation Proposed Rule

The Partnership for DSCSA Governance Is Up and Running

Early rejected Logo for the PDG

The most exciting thing happening lately with the Drug Supply Chain Security Act (DSCSA) is the setting up of a new non-profit organization aimed at coordinating the development of “…a comprehensive shared vision for interoperable drug tracing...” so all companies can comply in 2023 and beyond (See “PDSA’s Proposal for Governance of DSCSA Phase II Interoperability” and “PDSA Brainstorms Vision For DSCSA Governance Organization With Stakeholders“).  The Pharmaceutical Distribution Security Alliance (PDSA) initiated the development of that new organization last year and we now have its name:  The Partnership for DSCSA Governance, Inc., or PDG.  I am told their website will be set up in the next few weeks, so until then, I have posted several of their public documents for RxTrace readers.  Let’s take a look at them.

Continue reading The Partnership for DSCSA Governance Is Up and Running

…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance

DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of Dirk Rodgers. The material contained in RxTrace is not legal advice. Dirk Rodgers is not a lawyer.
The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel
and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating
the positions of any company, organization or individual other than Dirk Rodgers.

RxTrace, a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance.
Contact Us | Privacy Statement
Copyright © 2009-2020 Dirk Rodgers Consulting, LLC. All Rights Reserved.
RxTrace is a registered trademark of Dirk Rodgers Consulting, LLC